Navigation Links
Targeting des B-Zell-Rezeptors in aggressiven B-Zell-Lymphomen
Date:6/14/2013

STOCKHOLM, June 14, 2013 /PRNewswire/ --

Dr. Wyndham Wilson wird über aktuelle Entwicklungen bei der Behandlung von Lymphomen mit kleinen Molekülen berichten.

Obwohl in den vergangenen 30 Jahren eine wahre Fülle an Optionen zur Behandlung von diffusen großzelligen B-Zell-Lymphomen (DLBCL) entstanden ist, sind in diesem Bereich nur geringe Fortschritte erzielt worden. Aus neuesten Studien geht hervor, dass die Signalübertragung des B-Zell-Rezeptors für viele B-Zell-Lymphome ein entscheidender Faktor ist, darunter auch für den häufigsten Rezeptortyp - die sogenannten diffusen großzelligen B-Zell-Lymphome (DLBCL). Neueste Studien haben gezeigt, dass es sich bei DLBCL eigentlich um keine einzelne, sondern um mindestens 3 verschiedene Krankheiten handelt, von denen jede ganz eigene kritische Abnormalitäten aufweist, die das Überleben eines bösartigen Tumors begünstigen. Die am schwierigsten zu behandelnde Art von DLBCL wird als ABC-Subtyp (Activated B-cell) bezeichnet und hängt von einer abnormalen Signalübertragung des B-Zell-Rezeptors (BCR) ab. Untersuchungen von Dr. Lou Staudt haben gezeigt, dass derartige Tumoren absterben, sobald dieser Signaltransduktionsweg blockiert wird.

In Zusammenarbeit mit Dr. Lou Staudt, Pharmacyclics und Forschungskollegen haben wir eine klinische Studie eines äußerst potenten Inhibitors der Bruton-Tyrosinkinase (BTK) namens Ibrutinib durchgeführt. Die Hemmung der BTK durch Ibrutinib blockiert die abnormale BCR-Signalübertragung in ABC-DLBCL-Tumorzellen und tötet diese ab. In einer weiteren klinischen Studie, die mein Kollege im Zuge dieser EHA-Tagung präsentieren wird, zeigen wir, dass Tumoren von ABC-DLBCL-Patienten mithilfe von Ibrutinib abgetötet werden können. Noch wichtiger ist aber, das
'/>"/>

SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
2. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
3. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
4. Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
5. 3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
6. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
7. Allazo Health CEO at Wharton Health Care Conference Shows how Predictive Analytics and Individualized Intervention Targeting Promote Medication Adherence.
8. XCHC Releases Worldwide Growth Guidance For Its Cannabinoid Treatment Centers and Formulations Targeting Critical Human Ailments, Company Acts on Own Guidance
9. Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat
10. Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides
11. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... 30, 2015  Astellas Pharma Inc. (TSE: 4503) today ... on the safety, tolerability and efficacy of ASP2215, a ... refractory (R/R) acute myeloid leukemia (AML) were presented during ... Clinical Oncology,s (ASCO) annual meeting in Chicago ... kinase inhibitor of FLT3 and AXL, which are involved ...
(Date:5/30/2015)... Wash. and VANCOUVER, British Columbia ... Inc. (NASDAQ: OGXI ) announced today that results ... trial showed a benefit with custirsen therapy in men ... poor prognosis. The analysis, exploring the effect of clusterin ... that over 40 percent of men in the trial ...
(Date:5/30/2015)... y SPARTANBURG , Carolina ... - Nueva colaboración para ampliar drásticamente ... con cáncer en los Estados Unidos   ... Health proporcionarán a los pacientes con cáncer apoyo ... Guardian Research Network y Molecular Health han anunciado ...
Breaking Medicine Technology:Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) 2Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) 3OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 2OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 3OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 4OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 5OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 6Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 2Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 3Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 4
... Masimo (NASDAQ: MASI ) announced today that ... (RRa™) was presented at the New York ... Meeting in New York City. The new ... outcomes and patient safety impact of Masimo,s unique Acoustic Respiration ...
... /PRNewswire-iReach/ -- Physicians, Capital Investments, LLC (PCI/the ... and medical investment solutions is pleased to announce ... to Dallas, TX. The new headquarters, centrally located ... Company,s real estate development, business development and administrative ...
Cached Medicine Technology:New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 2New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 3New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 4New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 5Physicians' Capital Investments Announces Relocation of its Corporate Headquarters to Dallas, TX 2Physicians' Capital Investments Announces Relocation of its Corporate Headquarters to Dallas, TX 3
(Date:5/29/2015)... Displays and Exhibits’ has recently aligned with a new hanging ... signs ; making what was formerly an elite expensive ... points at a usual height of 16’-20’ are easily seen ... are very unique and more visible than the largest exhibits. ... labor and rigging the costs far outweigh the benefit of ...
(Date:5/29/2015)... 2015 Based in St. Louis, Missouri La ... for a couple of months now and are really ... which reads “I’m not misbehaving, I have Autism, please be ... of an autistic child in order to start a conversation ... only are they raising awareness through the autism awareness shirts ...
(Date:5/29/2015)... What does community do? , According to ... together to plant gardens, to teach young people, to ... critical issues. Community invites everyone to help improve lives ... Community Does" was commissioned by The Denver Foundation, the ... during the foundation’s Annual Celebration in May. At just ...
(Date:5/29/2015)... May 29, 2015 M3 USA MDLinx.com, ... in 14 medical specialties, now offers The Smartest ... spectrum of rheumatology disorders ranging from Fibromyalgia and Osteoporosis, ... editorial director of MDLinx, and Caroline Tredway, editorial head ... impact it will have on the physicians who participate. ...
(Date:5/29/2015)... Cincinnati, Ohio (PRWEB) May 29, 2015 ... Proven Experience to Cincinnati , The Department of Veterans ... John A. Gennaro as the new director of the ... of health care to more than 43,000 unique Veterans ... , With over 2,000 staff, CVAMC is a two-division ...
Breaking Medicine News(10 mins):Health News:Displays and Exhibits Announces New Hanging Sign Supplier 2Health News:La La Land Shirts Is Busy Spreading Autism Awareness with Complimentary Shipping on Their New Shirt 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:VA Healthcare System of Ohio Network Announces New Medical Center Director 2
... ... promotes Prize4Life. , ... (Vocus) March 24, 2010 -- In April of 2009, Director/Producer James Takata, Writers/Producers Zach ... Prize4Life’s battle against ALS. Trapped is a short film about Stephen, a talented young ...
... in Spanish . Barcelona, Spain: Recurrence ... tumour remains the strongest, independent prognostic factor for subsequent metastasis ... disease for a very long time, according to research presented ... Dr Sven Mieog, MD, a research fellow at Leiden ...
... release is available in Spanish . ... women are surviving breast cancer and delaying childbirth, it is ... fertility into consideration when deciding on treatment, the seventh European ... Dr. Anne Armstrong, from the Department of Medical Oncology, the ...
... after the death of a loved one can provide much-needed ... a study in the April issue of the Journal ... lost a relative to cancer took part in the study. ... included widows, widowers, daughters and sisters. Nine chose foot massage, ...
... Organic Relaxation Herbal ... the product works. This Herbal Tea can be purchased at Youmeandtea.com, , , ... (PRWEB) March 24, 2010 -- Organic Relaxation ... well the product works. This Herbal Tea can be purchased at Youmeandtea.com , ,"I ...
... ... obesity and empower kids to make healthy decisions. , ... (Vocus) March 24, 2010 -- To help kids to make healthy ... www.mvpkidpower.com on Facebook., , , , ,“Being on Facebook enables KidPower to actually ...
Cached Medicine News:Health News:Prize4Life Inspires Award-winning ALS Film: Trapped 2Health News:Prize4Life Inspires Award-winning ALS Film: Trapped 3Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 3Health News:Fertility issues in young women with breast cancer must be addressed 2Health News:Hand and feet massages provide consolation for bereaved relatives 2Health News:Snoring Reduced With Relaxation Tea… Could It Be? 2Health News:Snoring Reduced With Relaxation Tea… Could It Be? 3Health News:MVP Health Care Takes KidPower Youth Sports Program to Facebook 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: